



Press Release April 2017

GenoSafe announces the appointment of Jean-François Col as CEO



Jean-Francois Col, new CEO of GenoSafe

25th April 17 Evry, France.

GenoSafe SAS, a CRO which specializes in evaluating biotherapeutic products is pleased to announce the appointment of Jean-François Col as Chief Executive Officer. Jean-François Col holds a Master Degree in Genetics, Immunology, Pharmacology and Bio-Engineering from Lyon I Sciences University, France. He has an accurate knowledge of product development in small and emerging biotech companies and the associated risk management from financial challenges.

"I am extremely pleased to welcome Jean-François Col as a CEO. Jean-François demonstrates great expertise of customer relationships management as well as a passion to support our teams to secure the delivery of projects. I am sure his dynamism and engagement at every levels will boost our global expansion to better serve our clients" commented Dr Serge Braun, President of GenoSafe.

About Jean-François Col

Jean-François Col started his career in conducting clinical research in oncology related to multi-drug resistance at Pasteur Research Institute – in partnership with Hospital Edouard Herriot, Lyon. Following a first 12-year of new business development activities in discovery

technologies across Europe, he progressed his career through Baxter covering homecare services for rare diseases. Then he joined Covance, the global provider in preclinical, laboratory and analytical services. Lately, he moved to clinical trial world for an additional five years at Quintiles IMS (Saint Ouen, France) where he became Senior Director of Business Development for full service clinical trial offers to help SME and Pharma focused on rare and metabolic diseases.

About GenoSafe

GenoSafe is a full Contract Research Organization which specializes in evaluating the quality, safety and efficacy of advanced-therapy medicinal products.

We assist our client with customized services all along the development of their product, from the proof of concept through market launch.

GenoSafe develops, validates specific assays and performs samples analysis.

Our activities encompass 3 main domains of activities:

- Quality Control testing – Product characterization
- Preclinical development – In vitro testing
- Clinical Development – Follow-up of patients

Our core offering is based on expertise in complementary scientific fields: molecular biology, cell culture, virology and immunology.

Our clients benefit from our strong Quality Assurance policy. We perform our studies in strict compliance with regulatory (EMA, FDA) requirements.

For more information please contact GenoSafe by email: contact@genosafe.com.

